STATE OF MARYLAND Healthy People Healthy Communities Maryland Department of Health and Mental Hygiene

Larry Hogan, Governor - Boyd Rutherford, Lt. Governor - Dennis R. Schrader, Secretary

Laboratories Administration Robert A. Myers, Ph.D., Director

DATE: January 9, 2017

TO: Medical Laboratory Directors, Local Health Officers, and Health Care Providers

FROM: Robert A. Myers, Ph.D.

Director, Laboratories Administration

RE: Updated Guidance and Instructions for Submission of Specimens for Suspected Zika Virus

Infection Testing at the Maryland DHMH Laboratory (January 2017)

On Monday, January 9, 2017, the Maryland DHMH Laboratory will begin using the CDC developed Trioplex multiplex real-time PCR (RT-PCR) assay to detect Zika virus RNA in clinical specimens that have been pre-authorized for testing. The Trioplex assay is approved for use by the federal Food and Drug Administration (FDA) under an Emergency Use Authorization (EUA) and has the added advantage of being able to simultaneously screen certain acute specimen types for both chikungunya and dengue virus RNA. The DHMH Laboratory has performed extensive verification and validation studies in preparation for this test transition and found that the Trioplex assay demonstrated similar performance characteristics when compared to the existing single-plex Zika, dengue and chikungunya RT-PCR assays that are currently in use in our laboratory.

The procedures for preapproval of Zika testing at the DHMH Laboratory remain unchanged (see attached Guidelines and Instructions for Zika Testing) and testing of at-risk patients will continue to be performed in accordance with the most current CDC and DHMH guidance and algorithm (http://phpa.dhmh.maryland.gov/pages/zika.aspx). However, the types and volumes of specimens used in the Trioplex assay will be somewhat different (see attached Guidelines and Instructions for Zika Testing; Specimens Collection and Handling Table). The Trioplex assay has been validated and approved for use with larger volumes of serum which improves the sensitivity of the assay. Additionally, whole blood (purple top tube: EDTA anticoagulant) and cerebrospinal fluid (CSF) can also be tested in the Trioplex assay. Some studies have indicated that testing of whole blood during the acute phase of Zika infections might improve the detection of viral RNA. The use of plasma for Zika RT-PCR at the DHMH Laboratory is now discontinued. Please be aware that a serum specimen must be submitted along with the other specimen types that can be tested in the Trioplex PCR assay. Urine, CSF and whole blood specimens received without an accompanying serum cannot be tested in the Trioplex assay.

The DHMH Laboratory will continue to test serum specimens using the CDC developed FDA EUA approved Zika IgM antibody capture enzyme-linked immunosorbent assay (MAC-ELISA) for the presence of IgM antibodies. Extensive cross-reactivity in flavivirus serological assays has been documented. Therefore, if specimens are reactive in the Zika MAC-ELISA an additional paired convalescent serum might be required to complete additional plaque reduction neutralization testing (PRNT) testing at the CDC Laboratory to possibly identify the most recently infecting flavivirus.

Contact the DHMH Molecular Diagnostic Laboratory at (443) 681-3924 or (443) 681-3905 during normal business hours (8:00AM to 4:30 PM weekdays) for questions regarding the transition to the Trioplex assay for Zika virus RNA testing and the Arbovirus Serology Laboratory at (443) 681-3937 or (443) 681-3932 for inquires related to Zika virus IgM testing.

Howard Haft, MD, MMM. CPE, FACPE David Blythe, MD, MPH

PLEASE NOTE - REVISED CHART (01-10-2017)

Maryland Department of Health and Mental Hygiene Laboratories Administration Guidelines and Instructions for Zika Testing

A) Preapproval of Zika Test Requests

An infectious disease consultation with a Local Health Department (LHD) or DHMH is still required to authorize specimens for Zika virus testing at the MD DHMH Laboratory, prior to submitting specimens. Contact your Local Health Department or the DHMH Infectious Disease Epidemiology and Outbreak Response Bureau at (410) 767-6700 (or after hours, at (410) 795-7365) for consultation. Prior to contacting the LHD or DHMH, review of the current interim CDC guidance found in the link below, is highly recommended. http://phpa.dhmh.maryland.gov/pages/zika.aspx

B) Specimen Collection and Handling

Testing Category	Specimen Type (see notes 1 & 2)	Volume/Amount	Collect in:	Storage and Shipping Conditions (see note 3 for storage >5 days)
Symptomatic Adults and Children	Serum	3-5ml (6-10 ml blood draw)	Red top, tiger top, or gold top serum separator tube	Refrigeration (2-8°C)
Asymptomatic	Whole Blood	4-5 ml	Purple top EDTA tube	Refrigeration (2-8°C)
Pregnant Women Refer to	Urine	5-10 ml	Leak proof, sterile urine cup; label as urine	Refrigeration (2-8°C)
http://www.cdc.gov /zika/hc- providers/types-of- tests.html	Cerebral Spinal Fluid (CSF)	1-2 ml	Leak proof, sterile tube or vial; label as CSF	Refrigeration (2-8°C)
Infants (within 2 days of birth)	Serum	≥2 ml serum (≥4 ml blood draw)	Red top, tiger top, or gold top serum separator tube	Refrigeration (2-8°C)
Refer to CDC Guidelines on Collecting and	Urine	5-10 ml	Leak proof, sterile urine cup; label as urine	Refrigeration (2-8°C)
Submitting Specimens at Time of Birth for Zika Virus Testing http://www.cdc.gov /zika/hc- providers/test-	Fresh Placenta, Fetal Membranes, Umbilical Cord	inch square of: Umbilical cord Fetal membranes Placental disk edge Placental disk midsection Pathologic Lesions	Clearly labeled sterile cup with lid tightly closed; place each specimen in individually labeled cup	Refrigeration (2-8°C)
specimens-at-time- of-birth.html	Fixed Placenta, Fetal membrane, Umbilical Cord	l inch square of: Umbilical cord Fetal membranes Placental disk edge Placental disk midsection Pathologic Lesions	Fix specimens in formalin; volume of formalin used should be as small as possible, but about 10x mass of tissue.	Room Temperature

Notes:

- 1) A serum specimen must accompany all urine, CSF or whole blood specimens, or testing will not be performed.
- 2) Plasma will no longer be accepted for Zika testing at DHMH.
- 3) If specimens (except whole blood and fixed tissue) are to be held for longer than 5 days after collection until delivery to the testing lab, it is recommended to freeze to $\leq 20^{\circ}$ C and ship frozen (on dry ice). Avoid repeated freezing and thawing cycles. Whole blood EDTA should not be frozen but refrigerated and tested within one week of collection. Fixed tissues should be held and shipped at room temperature.

Alternative Specimen Types:

For detailed instructions on how to submit other specimen types (including amniotic fluid and semen) for Zika, dengue, chikungunya and other arboviral tests, contact the MD DHMH Laboratories at (443) 681-3924 or (443) 681-3937 during normal business hours from 8:00 a.m. - 4:30 p.m., Monday through Friday.

C) Complete the Test Request Form:

For detailed instructions about collecting and submitting specimens, refer to the attached instructions on the DHMH Serological Testing Request Form No. 4677 Sample Form or go to the MD DHMH Laboratories website (*insert replacement website for updated guidance doc*). This form **must** be completed when submitting pre-approved specimens for all Zika virus test requests to the DHMH Laboratory. Specimens submitted without this form or without prior approval from the Health Department will NOT be accepted for testing. **Please ensure that all required core demographic, provider, and patient contact information is completed**. In addition, please provide the following information to facilitate testing. Failure to include the additional clinical and epidemiological information will delay testing.

- **a.** Name of Health Department Person Approving Testing: Please record on the requisition the name of the DHMH or local health department person approving the testing.
- **b.** Clinical Illness/Compatible clinical presentation: e.g., rash, acute onset fever, conjunctivitis, arthralgia
- **c. Pertinent travel history**: Recent travel to a region where local transmission of Zika virus has been documented (an updated list is available at http://www.cdc.gov/zika/geo/index.html)
- d. History of any previous flavivirus infection: e.g., West Nile virus (WNV), dengue virus
- e. Acute illness onset date: contemporaneous with the travel exposures in areas of ongoing transmission (illness onset date ≤14 days after exposure)
- **f.** Immunization history: Yellow fever (YF), Japanese encephalitis (JE), or Tick-borne encephalitis (TE) vaccines

See the Following Attachments:

- 1) Illustrated directions for completing Form No. 4677
- 2) Blank test request Form No. 4677

D) Shipping:

Specimens collected for Zika virus testing can be transferred within the U.S. as Category B Biological substances in accordance with Department of Transportation (DoT) Hazardous Materials Regulations (49 CFR Part 171-180). Guidance for packaging samples in accordance with Category B Biological substance requirements can be found in the CDC/NIH Publication Biosafety in Microbiological and Biomedical Laboratories, 5th edition. Additional information about the DoT Hazardous Materials Transport Regulations can be found at https://www.transportation.gov/pipelines-hazmat. Appropriately packaged specimens can be directly shipped via a public carrier to the MD DHMH Laboratories Administration at the following address:

Maryland DHMH Laboratories Administration 1770 Ashland Avenue Baltimore, MD 21205

Or:

Contact your local health department for alternative arrangements to have specimens forwarded to the MD DHMH Laboratory. The DHMH Laboratory has routine couriers who pick up specimens from most of the local health departments on weekdays for delivery to the central lab in Baltimore for testing.

E) Inquiries About Testing

During normal business hours (8:30AM to 4:30 PM weekdays), for questions regarding the transition to the Trioplex assay for Zika virus RNA testing, please contact the DHMH Molecular Diagnostic Laboratory at 443-681-3924 or 443-681-3905 or the Arbovirus Serology Laboratory at 443-681-3937 or 443-681-3924 for inquiries related to Zika virus IgM testing.

Must complete the test request authorization information (This is where reports will be sent). Include the name of Healthcare provider who can legally order the test(s) in "Test Request Authorized by"

Request Arbovirus Travel-Associated Panel. Provide specimen source:

Indicate "S" for serum – (SST or aliquot) or whole clotted blood (red top)

Accompanying specimens*:

Indicate "**B**" for whole unclotted blood with EDTA (Purple top) UNSPUN

Indicate **"U"** for urine. (Leak-proof sterile urine cup)

Indicate "CSF" for Cerebrospinal fluid (Leak-proof sterile tube or vial)

*Urine, Whole blood, and CSF MUST be submitted with an accompanying serum specimen.

Complete patient's Travel history (location and dates), symptoms (or asymptomatic), pregnancy status (including weeks of gestation) vaccination history, & immune status

For questions on Zika Virus testing, please contact the lab: PCR: (443) 681-3923/3924 Serology: (443) 681-3932/3937

STATE LAB
Use Only 443-6

Laboratories Administration MD DHMH 1770 Ashland Ave. • Baltimore, MD 21205 443-681-3800 http://dhmh.maryland.gov/laboratories/ Robert A. Myers, Ph.D., Director

SEROLOGICAL TESTING



Patient's first & last names must

and exactly match the lab slip

be on the specimen container

4

	DEH DEP DATYPH DINOD II STD II TB II CD II COR		CD LICOR		W .
4	Health Care Provider		Patient SS# (last 4 dgits)		
de	Address		Last Name	DSR DJR DOBer	
E CC	Cay		First Namo	MI	
101	State Zp Code		Date of Buth (mm/dd/lyyyy)	1 1	
HL T	Contact Marne:		Address		
IJA	Phones		ASO .	Coumy	
NO IND	Test Request Authorized by.		Steam	Zip Code	
8 J 3	Sex CI Male C Female O Transgender M to F O Transgender F to M	Craneg	under FloM Ethnicity. Hispanic or Latino Organ?	Orgin? [] yes [] no	
HA	Race: America Indian/Alasta Native Rece:	reis	☐ Asiam ☐ Black/African American ☐ Native Hawanan/other Pacific Istander	other Pacific Islander White	
1 ac	MRN/Case# DOC#		Outbrack # Submit	Submitter Lab #	
E Oi	Date Collected	ollected	Bm Cpm "Veconation History.	Mory.	
9YT	Previous Test Done? no yes Name of Test		D1st Cl 2nd Cl 3nd	State Lab Number:	
	Name of Test		Date CTST 364 Sid	State Lab Number:	
	Ortset Dete: Exposure Date	rre Date	☐ Clinical Illness/Symptoms	oms.	
SPE 4	SPECIMEN SOURCE CODE	85 +	+ SPECIMEN SOURCE CODE	+ SPECIMEN SOURCE CODE	
	Arbovina Panela (Serura or CSF)		Herpes Simplex Vans (HSV) Types 1\$2	4 LAVENDER TOP TUBE REQUIRED	
Ma	Mandatory: Onset Date, Colection Date, and Yavel History		Legionella	Hemoglobin Disorders	
	Arbovius Endemic Panel (WNV, EEE. SLE LAC)		Leptospira	Blood transfusion? (last 4 months)	
	Arbovirus Travel-Associated Panel		Lyme Disease		
	(Chikungunya, Dengue)		*MARK/Intriumby Society (Measter		
3 .E	Based on information provided PCR and/or immunological assays will be performed.		(Rubeola), Mumps, Rubella, Varicella (Chickengos) loGAb only)	Father of balby screen? In yes In no Guardian's name if patient is a	L.
2 6	Required information, check all that apply. DIAGNOSIS: Discontic Meyonolis: Telepohalite		Mononucleosis - Infectious	Name of mother of 'at risk" baby	_
ŏ	Clother		Warms Immunity Screen		_
ì	The state of the s		Members		_
2 🗂	Datered mental state Diffusion weakiness Drash		Rocky Mountain Spotted Fever (RMSF)	RESTRICTED TEST	_
ŏ	□ other		*Rabies (RIFIT) (*List vaccination dates above)	Pre-Approved Submitters Only	_
=	RLNESS FATAL? Dyes Ono		*Rubella Immunity Screen	Sections a separate a pecimen for HIV	- 4
E	TRAVEL HISTORY (dates and places)		*Rubeola (Measles) Immunity Sorgan	http://dhmh.maryland.gov/laboratorig	_
			Schistosome	I HRV	_
2	MIMINIZATIONS: Yellow fever? yes no		Strongroides	Country of Origin	
i			Swphilis - Previously treated? was no	Band Jed Carther Mecahan	_
1	MARKUNG COMPRESSION LYSS IND		Toxoplesma		
Ť	Aspergillus		Tutanemia	00.00	_
Ť	Chlamydia (group antigen IgG)		Vancella Immunity Screen	after collection ves 0.00	
	Cryptococcai (antigen)		VDRL (CSF only)	_	
Ť	Cytomegalovinus (CMV)		CDC:Other Test(s)	Ωyes □no	
Ĩ	Ehrfichia	A	Add1 Specimen Codes	SPECIMEN SOURCE CODE	
Ī	Epstein-Barr Virus (EBV)		Prior arrangements have been made with the	S	_
	Hepatitis A Screen (IgM Ab only, acute infection)		following DHMH Labs Administration		
	Cell lab (443-581-3889) pnor lo submitting	L	- Cartesian Cart	CSF Cerebrospinal Fluid	
Ī	Hepatitis B Screen (HBs antigen only)		ZIKA VIĽUS		_
	Prematal patient? 🗆 yes 🗅 no		Approved by: ####		
	"Hepetitis B Panel: (HBsAg, HBsAb)	-		UR UPITAL	_
	"Hepatitis B post vaccine (HBsAb)	1			-
Ŧ	Hepatris C screen (HCV Ab only)	Ē	Please Note Vaccination History above*		_

Collection Date and Onset of symptoms Date MUST be completed

1

If specimens other than whole blood, urine, serum, or CSF are being requested, please note type of specimen here, e.g.:

Fresh or Fixed Tissue

Amniotic Fluid

You must write "Zika Virus" to request testing

Include the name of the Local Health Department or DHMH Epidemiologist who approved testing

STATE LAB Use Only

Laboratories Administration MD DHMH

1770 Ashland Ave. • Baltimore, MD 21205 443-681-3800 http://dhmh.maryland.gov/laboratories/ Robert A. Myers, Ph.D., Director



SEROLOGICAL TESTING

13/12	LEH FP MTY/PN NOD STD TB CD COR					OK Lhy		1,347						
E S	Health Care Provider					Patient SS# (last 4 digits):								
INFORMATION THREE COPIES	Address					Last Name						□ SR □ JR □ Oth	er	
RIM	City					First Na	ame			T. AV.		M.I.		
오본	State	ZIp Co	de	DE L		Date of Birth (mm/dd/yyyy)								
E T	Contact Name:					Addres	s				1010			
A A	Phone#	Fax#			PARTY.	City			HE I			County	111	
O O	Test Request Authorized	by:				State				aret.		Zip Code		
I R I	Sex: ☐ Male ☐ Female ☐ Transgender M to F ☐ Trans				nder F to M	1	Ethni	city: H	lispanic or	Latino Or	igin?	□ yes □ no		
TYPE OR PRINT REQUIRED INFORMATION OR PLACE LABELS ON ALL THREE COPIES	Race: American India	/e 🗆 A:	Asian Black/African American Native Hawaii				waiian/oth							
	MRN/Case # DOC #				Outh	reak#				Submitter	Lab	#		
	Date Collected: Time Colle					□a	am 🗆	om	*Vaccinat	on Histor	ry: _			
	Previous Test Done? ☐ no ☐ yes Name of Test								□ 2nd □	3rd S	State Lah Number			
	Name of Test					ate		1st	□ 2nd □	3rd Si	State Lab Number:			
	Onset Date: Exposure													
♣ SPE	CIMEN SOURCE CODE			♣ SPE	CIMEN S	DURCE (CODE					ECIMEN.SOURCE CODE		
Arbovirus Panels (Serum or CSF)									pes 1&2		_	VENDER TOP TUBE REQUI	en.	
Mandatory: Onset Date, Collection Date, and Travel History			listory	Herpes Simplex Virus (HSV) Types 1&2 Legionella				Hemoglobin Disorders						
Arbovirus Endemic Panel (WNV, EEE, SLE, LAC)				Leptospira			_	Blood transfusion? (last 4 months)						
Arbovirus Travel-Associated Panel (Chikungunya, Dengue) Based on information provided PCR and/or immunological assays will be performed. Required information, check all that apply: DIAGNOSIS: Baseptic Meningitis Encephalitis				Lyme Disease				□ yes □ no						
			•)	*	MMRV Im	munity S	Screen:	[Me	easles		Prenatal screen? ☐ yes ☐ no			
			ľ		(Rubeola				•	×	Father of baby screen? ☐ yes ☐ no Guardian's name if patient is a minor:			
					(Chicken				-					
			alitis	Mononucleosis - Infectious						Name of mother of "at risk" baby:				
SYMPTOMS: □headache □fever □stiff neck □altered mental state □muscle weakness □rash □other □ILLNESS FATAL? □yes □no TRAVEL HISTORY (dates and places) IMMUNIZATIONS: Yellow fever? □yes □no Flavivirus? □yes □no				*Mumps Immunity Screen						- Taking of Mellor of deflor Saby.				
				Mycoplasma					_					
					Rocky Mou		otted F	ever ((RMSF)			RESTRICTED TEST		
				*Rabies (RFFIT) (*List vaccination dates above)					ve)		Pre-Approved Submitters Or			
				*Rubella Immunity Screen *Rubeola (Measles) Immunity Screen					Sub	omit a separate specimen fo instructions go to:	r HIV			
									http://dhmh.maryland.gov/laboratorles/					
				Schistosoma					-	HIV				
				Strongyloides			C	Country of Origin						
18.48	MUNOCOMPROMISED?	. □ yes □n		s	vphllis - F	reviously	/ treate	d? □	yes □ no	-		apid Test: Reactive N	o a a thua	
11411	WONOCOMPROMISED?	□ yes □	° F	_	oxoplasm				,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,				egauve	
1	Aspergillus	15		T	ularemla				,			ate:		
	Chlamydia (group antigen l	gG)		V	aricella In	nmunity S	Screen					pecimen stored refrigerated (2		
Chlamydia (group antigen IgG) Cryptococcal (antigen)			VDRL (CSF only)					after collection. □ yes □ no Specimen transported on cold packs						
(Cytomegalovirus (CMV)			CDC/Other Test(s)					☐ yes ☐ no					
E	Ehrlichia Epsteln-Barr Virus (EBV)				pecimen	Codes _				SI	SPECIMEN SOURCE CODE: PLACE CODE IN BOX NEXT TO TEST B Blood (5 ml)			
8					Orior Arra	naamant	a have	haan		DI				
Hepatitis A Screen (IgM Ab only, acute infection)					following				made with ration	uie				
	Call lab (443-681-3889) prior to submitting Hepatitis B Screen (HBs antigen only) Prenatal patient? ☐ yes ☐ no			employee:				_	CSF Cerebrospinal Fluid L Lavender Top Tube P Plasma S Serum (1 ml per test)					
								- 1						
*Hepatitis B Panel: (HBsAg, HBsAb)										UR Urine				
*	Hepatitis B post vaccine (F	HBsAb).		-						_				
F	lepatitis C screen (HCV At		Please Note Vaccination History above*											
LIAMI ART	77 Revised 08/15												- 1	